Phase II/III Study Trends and Market Outlook (2016-2020)

  • ID: 4035518
  • Report
  • Region: Global
  • 74 Pages
  • Industry Standard Research (ISR)
1 of 4

In much of our research, we make a point to ask respondents for their outlook on market changes or trends they expect to occur regarding a specific topic. To this end, a research effort was dedicated to providing a broad view into the industry’s perspectives on the clinical development market. For this report, 112 Phase II/III decision-makers were surveyed to gather their insights into where the Phase II/III market is expected to head over the next four years. This report is designed to assist those interested in the Phase II/III market in not only remaining current with market happenings but in getting a jump on what the market is expected to look like in 2020.

What You Will Learn:

  • 4-year examination of the industry’s Phase II/III market dynamics (i.e. study volume, outsourced spend)
  • Average dollar value of outsourced Phase II/III studies and how this varies by sponsor size
  • Criteria sponsors use to select (and disqualify) clinical service providers
  • Current and future use of adaptive trials and risk-based monitoring in Phase II/III trials

How you can use this report:

  • Gain understanding of the key decision-makers within sponsor organizations to develop more targeted communications
  • Learn the most desirable characteristics of a Phase II/III service provider
  • Discover the expansion into developing markets
Note: Product cover images may vary from those shown
2 of 4

1. Introduction
 
2. Methodology

3. Respondent Demographics & Qualifications

  • Executive Summary
  • Market Dynamics
  • Spend On Phase II/III Studies
  • Outsourced Proportion Of Phase Ii/Iii Spend
  • Average Value Of Outsourced Phase Ii/Iii Study
  • Forces Leading To Potential Change In Phase Ii/Iii Outsourcing
  • Outsourced Spend By Provider Type
  • Provider Perceptions And Selection
  • Departmental Decision-Making Influence
  • Number Of Preferred Providers
  • Difficulty Using Non-Preferred Providers
  • Desired Provider Characteristics
  • Provider Selection Attributes
  • Trends And Predictions
  • Locations Of Phase Ii/Iii Studies
  • Preference For Small Cros
  • Working Solely With Large Cros
  • Consolidation Of Cro Spend
  • Recruiting In China And India
  • Sponsor Interest In Pediatric And Orphan Drug Development
  • Adaptive Design Use
  • Change In Adaptive Trial Use
  • Risk-Based Monitoring Use
  • Change In Risk-Based Monitoring Use
  • Use Of Multiple Countries
  • Change In Conducting Trials In Multiple Countries

4. Study Data

  • Market Dynamics
  • Spend On Phase II/III Studies
  • Outsourced Proportion Of Phase II/III Spend
  • Average Value Of Outsourced Phase II/III Study
  • Potential Forces Leading To An Increase In Phase II/III Outsourcing
  • Potential Forces Leading To An Decrease In Phase II/III Outsourcing
  • Outsourced Spend By Provider Type
  • Benefits Of Large, Full-Service Cros
  • Benefits Of Using Mid-Size, Multi-Service Cros
  • Benefits Of Using Small Or Niche Service Cros
  • Benefits Of Using Academic Medical Centers
  • Locations Of Phase Ii/Iii Studies
  • Provider Perceptions And Selection
  • Service Provider Familiarity
  • Number Of Preferred Providers
  • Difficulty Using Non-Preferred Providers
  • Service Provider Use
  • Service Provider Preference
  • Reason For Service Provider Preference
  • Desired Provider Characteristics
  • Provider Selection Attributes
  • Reasons Providers Lose Bids
  • Departmental Decision-Making Influence
  • Trends And Predictions
  • Preference For Smaller Cros
  • Working Solely With Large Cros
  • Study Size Impact On Cro Consideration
  • Consolidation Of Cro Spend
  • Recruiting In China
  • Recruiting In India
  • Change In Sponsor Interest In Orphan Drug/Rare Disease Compounds
  • Change In Sponsor Interest In Pediatric Drug Development
  • Adaptive Design Use
  • Change In Adaptive Trial Use
  • Risk-Based Monitoring Use
  • Change In Risk-Based Monitoring Use
  • Use Of Multiple Countries
  • Change In Conducting Trials In Multiple Countries
  • Change In Use Of Hospitals Or Academic Centers

Respondent Demographics

  • Company Type
  • Areas Of Responsibility
  • Drug Development Responsibilities
  • Respondent Location
  • Job Title
  • Recent Outsourcing Involvement
  • Drug Development Involvement
  • Drug Development Involvement By Phase
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll